Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02484729
Other study ID # D6400C00001
Secondary ID 2015-000877-11
Status Completed
Phase Phase 1
First received June 18, 2015
Last updated November 24, 2015
Start date July 2015
Est. completion date November 2015

Study information

Verified date November 2015
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

This study will be a randomized, single-blind, placebo-controlled first-in-human study in healthy male subjects to assess the safety, tolerability and pharmacokinetics of single ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along the gastro-intestinal tract will be investigated using the IntelliCap® system in a non-randomized, open-label, fixed-sequence design. The study will be performed at a single study centre.


Description:

This study will be a randomized, single-blind, placebo-controlled first-in-human study in healthy male subjects to assess the safety, tolerability and pharmacokinetics of single ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along the gastro-intestinal tract will be investigated using the IntelliCap® system in a non-randomized, open-label, fixed-sequence design with oral solution as reference. The study will be performed at a single study centre.


Recruitment information / eligibility

Status Completed
Enrollment 88
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Provision of signed and dated written informed consent prior to any study specific procedures.

2. Healthy male subjects aged 18 to 50 years with suitable veins for cannulation or repeated venipuncture.

3. Male subjects have to comply with the restrictions for sexual activity provided to them.

4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.

5. Optional: Provision of signed and dated written informed consent for genetic research.

If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.

6. Able to understand, read and speak the English language.

Exclusion Criteria:

1. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study, or influences the results or the potential subject's ability to participate in the study.

2. History or presence of GI, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.

3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of dosing in Part A or the first dose of AZD9977 in Part B.

4. Any clinically significant abnormalities in hematology, clinical chemistry or urinalysis results, as judged by the investigator.

5. Any positive result at screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody, and human immunodeficiency virus (HIV) antibodies.

6. Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:

- Systolic blood pressure (SBP) < 90 mmHg or = 140 mmHg

- Diastolic blood pressure (DBP) < 50 mmHg or = 90 mmHg

- Pulse < 45 or > 90 bpm

7. Any clinically important abnormalities in rhythm, conduction or morphology of the electrocardiogram (ECG) at screening or pre-dose, as considered by the investigator.

8. Prolonged QTcF > 450 ms or family history of long QT syndrome.

9. PR (PQ) interval shortening < 120 ms. PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation.

10. PR (PQ) interval prolongation > 240ms; intermittent second or third degree atrioventricular (AV) block, or AV dissociation.

Wenckebach block while asleep is not exclusive.

11. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms.

QRS > 110 ms but < 115 ms are acceptable if there is no evidence of ventricular hypertrophy or pre-excitation.

12. Serum potassium higher than 5.0 mmol/L at screening or admission to the study center (Day -1).

13. Known or suspected history of drug abuse as judged by the investigator.

14. Current smokers or those who have smoked or used nicotine products within the previous 3 months.

15. History of alcohol abuse or excessive intake of alcohol as judged by the investigator.

16. Positive screen for drugs of abuse, alcohol or cotinine at screening or admission to the study center.

17. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.

18. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea and chocolate) as judged by the investigator.

19. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to dosing in Part A or the first dose of AZD9977 in Part B.

20. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during 2 weeks prior to dosing in Part A or the first dose of AZD9977 in Part B, or longer if the medication has a long half-life.

21. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.

22. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of dosing in Part A or the first dose of AZD9977 in Part B in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.

Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.

23. Involvement of any AstraZeneca or study site employee or their close relatives.

24. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.

25. Subjects who are vegans or have medical dietary restrictions (vegetarians may be included in the study).

26. Subjects who cannot communicate reliably with the investigator.

27. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

28. Previous bone marrow transplant.

29. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.

Criteria applicable to Part B only:

30. Subjects with pacemakers or other implanted electro-medical devices.

31. Subjects with swallowing disorders.

32. Subjects with pre-planned MRI examination.

33. Subjects not willing to have an abdominal X-ray performed if the IntelliCap® capsule has not been retrieved within one week after ingestion.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
AZD9977, oral suspension
Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
Placebo, oral suspension
Matching placebo
AZD9977, oral solution
AZD9977, single dose of oral solution in Part B as reference

Locations

Country Name City State
United Kingdom Research Site Harrow

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of AZD9977 by assessing the number of adverse events To assess the safety and tolerability of single ascending doses of AZD9977 For up to 45 days, i.e. from Screening to Follow-up Yes
Primary Safety and tolerability of AZD9977 by assessing pulse rate To assess the safety and tolerability of single ascending doses of AZD9977 For up 45 days, i.e. from Screening to Follow-up Yes
Primary Safety and tolerability of AZD9977 by assessing 12-lead electrocardiograms To assess the safety and tolerability of single ascending doses of AZD9977 For up 45 days, i.e. from Screening to Follow-up Yes
Primary Safety and tolerability of AZD9977 by cardiac telemetry To assess the safety and tolerability of single ascending doses of AZD9977 For up 4 days, i.e. on the day before each dosing and for 24 hours after each dosing Yes
Primary Safety and tolerability of AZD9977 by assessing the number of subjects with adverse events To assess the safety and tolerability of single ascending doses of AZD9977 For up to 45 days, i.e. from Screening to Follow-up Yes
Primary Safety and tolerability of AZD9977 by assessing blood pressure To assess the safety and tolerability of single ascending doses of AZD9977 For up 45 days, i.e. from Screening to Follow-up Yes
Primary Safety and tolerability of AZD9977 by assessing hematology To assess the safety and tolerability of single ascending doses of AZD9977 For up 45 days, i.e. from Screening to Follow-up Yes
Primary Safety and tolerability of AZD9977 by assessing clinical chemistry To assess the safety and tolerability of single ascending doses of AZD9977 For up 45 days, i.e. from Screening to Follow-up Yes
Primary Safety and tolerability of AZD9977 by assessing urinalysis To assess the safety and tolerability of single ascending doses of AZD9977 For up 45 days, i.e. from Screening to Follow-up Yes
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1